Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population

Conclusion Gefitinib, erlotinib, and afatinib have similar effectiveness in advanced stage N SCLC with EGFR mutation positive. Afatinib tends to be associated with longer PFS but further investigation is required. DOI: 10.3779/j.issn.1009-3419.2019.09.02
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research

Related Links:

ConclusionSurgical-resected c-SCLCs have a relatively good prognosis. TNM stage is the most significant factor influencing disease progression in surgical-resected c-SCLCs. SUVmax and mixed NSCLC components within c-SCLCs had a considerable influence on the survival. Both high SUVmax and mixed SCC component are poor predictors for patients with c-SCLCs.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
In conclusion, this is the first study that shows A549 and H460 cells expressed two distinctive isoforms of CD74 but isoform at 41 kDa was absent. Due to the absence of this isoform, the direct physical interaction between them CD74 and CD44 was lacking. Furthermore, the data also demonstrated that lacking of direct physical interaction between CD74 and CD44 had no effect on NF-κB activation and PGE2 production indicating that CD74-mediated downstream signaling occurs either through coreceptors or indirect interaction with CD44 in human lung cancer cells. ABBREVIATION: CD: cluster of differentiation; SCLC: small ...
Source: Immunological Investigations - Category: Allergy & Immunology Tags: Immunol Invest Source Type: research
rig Peter Sinn Moritz von Winterfeld Claus Peter Heussel Felix J. F. Herth Frederick Klauschen Albrecht Stenzinger Katharina Kriegsmann Reliable entity subtyping is paramount for therapy stratification in lung cancer. Morphological evaluation remains the basis for entity subtyping and directs the application of additional methods such as immunohistochemistry (IHC). The decision of whether to perform IHC for subtyping is subjective, and access to IHC is not available worldwide. Thus, the application of additional methods to support morphological entity subtyping is desirable. Therefore, the ability of conv...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Small cell lung cancer (SCLC) is considered to be a highly neuroendocrine malignant tumor because of its high rate of recurrence and metastasis, accounting for approximately 15-20% of lung cancer [1,2].According to the 1999 World Health Organization(WHO) classification of lung tumors, SCLC can be divided into two types: pure SCLC (P-SCLC) and combined SCLC (C-SCLC) [3].C-SCLC is defined by the 2015 WHO as small-cell carcinoma (SCLC) combined with additional components that consist of any histological types of non-small-cell lung carcinoma (NSCLC): adenocarcinoma (ADC),squamous-cell carcinoma(SCC),large-cell carcinoma(LCC),...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Immune checkpoint inhibitors (ICIs) are currently used as monotherapy or combination therapy in frontline and subsequent lines for metastatic lung cancer including adenocarcinoma, squamous cell carcinoma, and small cell lung cancer (SCLC) [1 –5]. Furthermore, ICIs before or after surgery showed efficacy in patients with resectable disease, highlighting the potential of ICIs to improve outcomes in these patients and expand the use of ICIs in the neoadjuvant and adjuvant settings [6,7]. Despite higher response rates, longer duration of response, and less toxicity of ICIs compared with chemotherapy, many lung cancer pat...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Lung cancer is the leading cause of cancer-related deaths mainly attributable to metastasis, especially extrathoracic metastasis. This large-cohort research is aimed to explore metastatic profiles in different histological types of lung cancer, as well as to assess clinicopathological and survival significance of diverse metastatic lesions. Lung cancer cases were extracted and enrolled from the Surveillance, Epidemiology, and End Results (SEER) database. χ2-tests were conducted to make comparisons of metastatic distribution among different histological types and odds ratios were calculated to analyze co-occurrence rela...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: [68Ga]-NeoBOMB1 uptake allowed detection of primary and metastatic lesions in patients with different tumor types, although tumor-specific uptake was variable and warrants further investigation. [68Ga]-NeoBOMB1 was well tolerated, with no related adverse events, consistent with the safety profile in previous studies. Whole-body dosimetry data were consistent with previous results in patients with gastrointestinal stromal tumors.1 The findings support further clinical development of NeoB (formerly known as NeoBOMB1) in a theragnostic approach using [68Ga]-NeoB to identify patients with GRPR-positive malignancie...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Basic Oncology & amp; Translational III Source Type: research
Conclusion: Among this large cohort, our center seems to follow the global trend with increasing incidence of ADC. EGFR mutation positivity was similar to existing reports, while higher ALK positivity was detected. A characteristic phenotype of never-smokers with lung cancer was elucidated which demonstrated better survival.
Source: Lung India - Category: Respiratory Medicine Authors: Source Type: research
Lung cancer can be classified into two main categories: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), which are different in treatment strategy and survival probability. The lung CT images of SCLC and NSCLC are similar such that their subtle differences are hardly visually discernible by the human eye through conventional imaging evaluation. We hypothesize that SCLC/NSCLC differentiation could be achieved via computerized image feature analysis and classification in feature space, as termed a radiomic model. The purpose of this study was to use CT radiomics to differentiate SCLC from NSCLC adenocarc...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Somatic alterations in the epidermal growth factor receptor gene (EGFR) result in aberrant activation of kinase signaling and occur in ∼15% of non-small cell lung cancers (NSCLC). Patients diagnosed with EGFR-mutant NSCLC have good initial clinical response to EGFR tyrosine kinase inhibitors (EGFR TKIs), yet tumor recurrence is common and quick to develop. Mechanisms of acquired resistance to EGFR TKIs have been studied extensively over the past decade. Great progress has been made in understanding two major routes of therapeutic failure: additional genomic alterations in the EGFR gene and activation of alternative kin...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | China Health | Indonesia Health | Lung Cancer | Non-Small Cell Lung Cancer | Small Cell Lung Cancer | Statistics | Study | Tarceva